Company profile
Moderna, Inc.
NASDAQ: MRNA · Healthcare · Biotechnology
#113 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
53DFH 52DQ 67GM 14SS 75
v0.1 · 65/100 weight · provisional
↑ market scale, filing timeliness · ↓ Piotroski F, growth stability
Methodology →Revenue TTM
$2.2B
Rev growth YoY (TTM)
-29.1%
Net income (FY)
-$2.8B
Employees
4,700
as of 2026-08-05
Market cap
$22.6B
as of 2026-08-05
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9B$1.9B2025
Net income-$2.8B-$2.8B2025
Operating income-$3.1B-$3.1B2025
Total assets$12.3B$12.3B2025
Liabilities$3.7B$3.7B2025
Equity$8.7B$8.7B2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product Sales100%
By geography
UNITED STATES65%
Rest Of The World33%
Europe3%
The read
What is Moderna, Inc.’s revenue?
Moderna, Inc. booked $1.9B in FY2025 revenue, contracting 40% year over year — slower than 79% of Healthcare companies we track, at a -145.2% net margin.
Peers · Healthcare
Privia Health Group, Inc.68BRadNet, Inc.73BTeleflex Incorporated77B+Clover Health Investments, Corp.58CPediatrix Medical Group, Inc.76B+Evolent Health, Inc.59CNeighbors
Middlesex →Key facts
CEOStéphane Bancel
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: MRNA
Employees4,700
IPO date2018-12-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.